9 Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan

10 Molecular epidemiology of Clostridium difficile in two tertiary care hospitals in Shandong Province, China

11 Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis

12 Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value

13 National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China

14 An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes

15 Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patients

16 Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

17 Community-acquired Clostridium difficile infection: an increasing public health threat

18 Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

19 Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile

20 Pomegranate extract specifically inhibits Clostridium difficile growth and toxin production without disturbing the beneficial bacteria in vitro

21 Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan

22 Molecular epidemiology of Clostridium difficile in two tertiary care hospitals in Shandong Province, China

23 Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis

24 Endogenous Clostridium perfringens Panophthalmitis with Potential Entry Port from Diverticulitis Exacerbated by Proliferative Diabetic Retinopathy

25 Decreased Clostridium Abundance after Electroconvulsive Therapy in the Gut Microbiota of a Patient with Schizophrenia

26 Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value

27 National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China

28 An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes

29 Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patients

30 Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

31 Community-acquired Clostridium difficile infection: an increasing public health threat

32 Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

33 A Novel Quantitative Sampling Technique for Detection and Monitoring of Clostridium difficile Contamination in the Clinical Environment.

34 Integrated genomic epidemiology and phenotypic profiling of Clostridium difficile across intra-hospital and community populations in Colombia

35 σ <sup>54</sup> (σ <sup>L</sup> ) plays a central role in carbon metabolism in the industrially relevant Clostridium beijerinckii

36 Correction to: Fed-batch acetone-butanol-ethanol fermentation using immobilized Clostridium acetobutylicum in calcium alginate beads (Korean Journal of Chemical Engineering, (2019), 36, 6, (909-913), 10.1007/s11814-018-0232-z)

37 Analyses of miRNA in the ileum of diarrheic piglets caused by Clostridium perfringens type C.

38 Clostridium perfringens enterotoxin-based protein engineering for the vaccine design and delivery system

39 Growth of Clostridium perfringens in cooked chicken during cooling: One-step dynamic inverse analysis, sensitivity analysis, and Markov Chain Monte Carlo simulation

40 Clostridium botulinum Spores Found in Honey from Small Apiaries in Poland

41 Implementation of a Checklist to Reduce False-Positive Testing in Hospital-Acquired Clostridium Difficile Infection.

42 Erratum: Correction for Kraft et al., "A Laboratory Medicine Best Practices Systematic Review and Meta-analysis of Nucleic Acid Amplification Tests (NAATs) and Algorithms Including NAATs for the Diagnosis of Clostridioides (Clostridium) difficile in Adults" (Clinical microbiology reviews (2019) 32 3 PII: e00128-19)

43 Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease.

44 Clostridium difficile: Is it a new food-borne pathogen?

45 Use of fluorescent CTP1L endolysin cell wall-binding domain to study the evolution of Clostridium tyrobutyricum during cheese ripening.

46 Effect of detoxification methods on ABE production from corn stover hydrolysate by Clostridium acetobutylicum CICC 8016.

47 Flooding-Associated Soft Rot of Sweetpotato Storage Roots Caused by Distinct Clostridium Isolates

48 Detection of Clostridium perfringens toxinotypes, enteropathogenic e. coli, rota and corona viruses in the intestine of neonatal goat kids by molecular techniques

49 Clostridium cellulovorans metabolism of cellulose as studied by comparative proteomic approach.

50 Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance

51 Butanol production from cellulosic material by anaerobic co-culture of white-rot fungus Phlebia and bacterium Clostridium in consolidated bioprocessing.

52 Thermodynamic Analysis of Glycolysis in Clostridium thermocellum and Thermoanaerobacterium saccharolyticum Using C and H Tracers.

53 The tcdA negative and tcdB positive Clostridium difficile ST81 clone exhibits high-level fluoroquinolone resistance: a multi-center study in Beijing, China.

54 Evaluation of factors influencing the growth of non-toxigenic Clostridium botulinum type E and Clostridium sp. in high-pressure processed and conditioned tender coconut water from Thailand

55 Systematic Review of Intestinal Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection

56 Bacterial Diarrhea in HIV-Infected Patients: Why Clostridium difficile, and Why Now?

57 Clostridium difficile infection in fever patients with gynecological malignancies

58 Staggered and Tapered Antibiotic Withdrawal With Administration of Kefir for Recurrent Clostridium difficile Infection

59 Antimicrobial Resistance Gene Acquisition and Depletion Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

60 Differences of the Fecal Microflora With Clostridium difficile Therapies

61 Clostridium difficile Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship

62 Prospective assessment of Clostridioides (formerly Clostridium) difficile colonization and acquisition in hematopoietic stem cell transplant patients

63 Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

64 Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients

65 Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens.

66 Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections

67 Epidemiology of community-acquired Clostridium difficile-associated diarrhea

68 A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+)

69 Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study

70 Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections

71 Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study

72 Evolving Insights Into the Epidemiology and Control of Clostridium difficile in Hospitals

73 Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial

74 Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection

75 A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile–associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

76 Comparison of clindamycin, rifampin, tetracycline, metronidazole, and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens

77 Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection

78 Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens

79 Patient Attitudes Toward the Use of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium difficile Infection

80 Prevalence and Pathogenicity of Clostridium difficile in Hospitalized Patients: A French Multicenter Study

81 Factors affecting initiation of growth of Clostridium botulinum

82 Renal Failure and Leukocytosis Are Predictors of a Complicated Course of Clostridium difficile Infection if Measured on Day of Diagnosis

83 Pathway to Prevention of Nosocomial Clostridium difficile Infection

84 Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial

85 Duodenal infusion of donor feces for recurrent Clostridium difficile

86 Risk factors for Clostridium difficile toxin-associated diarrhea

87 John G. Bartlett: Contributions to the Discovery of Clostridium difficile Antibiotic-Associated Diarrhea

88 Prevention of Clostridium difficile Infection With Probiotics

89 Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): Characterization, Manufacture, Mechanisms of Action, and Quality Control of a Specific Probiotic Combination for Primary Prevention of Clostridium difficile Infection

90 Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

91 Epidemiology and outcome of Clostridium difficile infection and diarrhea in HIV infected inpatients

92 Diarrhea and Clostridium difficile Infection in Latin American Patients with AIDS

93 Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection

94 Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection

95 Clostridium difficile-associated diarrhea in HIV-infected patients: epidemiology and risk factors

96 Epidemiology of Community-Acquired Clostridium difficile-Associated Diarrhea

97 Comparison of Clindamycin, Rifampin, Tetracycline, Metronidazole, and Penicillin for Efficacy in Prevention of Experimental Gas Gangrene Due to Clostridium perfringens

98 The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida

99 Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015

100 clostridium perfringens e a enterite necrótica em frangos: principais fatores de virulência, genéticos e moleculares

101 pseudomembranous colitis: not always caused by clostridium difficile

Keyword Connections

Journals

Research Groups

Bibliographies